ASH 2022 | Therapies for patients who progress on JAK inhibitors: imetelstat, navtemadlin, selinexor & TP-3654
In this video, Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights several agents being explored for the treatment of patients with myelofibrosis (MF) who progress on or develop resistance to JAK inhibitors. First, Dr Bose speaks on imetelstat and navtemadlin, two novel agents currently being investigated in Phase III trials, and further outlines recent data on selinexor in combination with ruxolitinib. Dr Bose further anticipates that TP-3654, a novel PIM kinase inhibitor, will be a promising agent in this setting, as early results from a trial demonstrated spleen and symptom responses and cytokine reduction. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; Morphosys: Honoraria, Research Funding; Kartos: Honoraria, Research Funding; Sierra Oncology: Honoraria; Karyopharm: Honoraria; Ionis: Research Funding; Incyte: Honoraria, Research Funding; CTI BioPharma: Honoraria, Research Funding; PharmaEssentia: Honoraria; Cogent: Honoraria, Research Funding; Blueprint: Honoraria, Research Funding; BMS: Honoraria, Research Funding; AbbVie: Honoraria; Promedior: Research Funding.
